ClinicalTrialsFinder
RecruitingPhase 2NCT07447050

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

RiluzolE FOr Preventing Cognitive DysfUnction in Cancer PatientS Receiving Chemotherapy (REFOCUS)

Sponsor

University of California, Irvine

Enrollment

24 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Breast CancerSarcomaLung CancerHead and Neck CancerGastric (Stomach) Cancer

Summary

This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Female and male patients diagnosed with cancer and planned to receive an anthracycline- or platinum- containing chemotherapy regimen.
  • ≥18 years of age.
  • Life expectancy \> 6 months
  • Able to provide informed consent.
  • Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.

Exclusion Criteria8

  • Presence of primary brain tumors or brain metastases.
  • Receive a primary chemotherapy regimen that does not include anthracycline- or platinum- containing chemotherapy.
  • Unwilling to undergo neuropsychological assessments necessary for the study.
  • Patients who are breastfeeding, pregnant or are planning to get pregnant during the study period. POCBP must have a negative pregnancy test at screening if there is suspicion of pregnancy. Patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.
  • History of or suspected hypersensitivity to riluzole or to any of its excipients.
  • Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.
  • Hepatic impairment as indicated by: AST and/or ALT ≥ 3 X upper limit normal (ULN).
  • Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.

Interventions

DRUGRiluzole

Given PO

OTHERPlacebo

Given PO

Locations(1)

Chao Family Comprehensive Cancer Center, University of California Irvine

Orange, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07447050

Related Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations

Empathic Communication Skills (ECS) Training

NCT0545684112 locations

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

NCT069260753 locations

Cardiac Outcomes With Near-Complete Estrogen Deprivation

NCT053096553 locations

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT041190243 locations